Article thumbnail

Epstein–Barr virus LMP2A imposes sensitivity to apoptosis

By Michelle Swanson-Mungerson, Rebecca Bultema and Richard Longnecker


In cell lines, the Epstein–Barr virus (EBV)-encoded protein latent membrane protein 2A (LMP2A) protects B-cells from apoptosis by blocking B-cell receptor (BCR) signalling. However, EBV-infected B-cells in vivo are extremely different from cell lines. This study used a murine transgenic model in which B-cells express LMP2A and a BCR specific for hen egg lysozyme to determine whether LMP2A protects resting and antigen-activated B-cells from apoptosis. LMP2A allows BCR signal transduction and induces constitutive activation of NF-κB to increase Bcl-2 levels that afford LMP2A-mediated protection from apoptosis in the absence or presence of antigen. In contrast, low levels of NF-κB inhibitor only affected Bcl-2 and Bcl-xL levels and increased apoptosis in LMP2A-negative B-cells after BCR cross-linking. These data suggest that LMP2A uniquely makes resting B-cells sensitive to NF-κB inhibition and apoptosis and suggest that NF-κB may be a novel target to eradicate latently EBV-infected B-cells

Topics: Animal
Publisher: Society for General Microbiology
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2008). An auto-regulatory loop for EBV LMP2A involves activation of Notch. Virology 371,
  2. (2006). Antigen-receptor signaling to nuclear factor kB.
  3. (1996). bcl-x exhibits regulated expression during B cell development and activation and modulates lymphocyte survival in transgenic mice.
  4. (2002). CD40 ligation downregulates EBNA-2 and LMP-1 expression in EBV-transformed lymphoblastoid cell lines.
  5. (2007). Cytokine secretion and latent herpes virus reactivation with 28 days of horizontal hypokinesia.
  6. (2004). Demonstration of the Burkitt’s lymphoma Epstein-Barr virus phenotype in dividing latently infected memory cells in vivo.
  7. (2008). EBV LMP2A affects LMP1-mediated NF-kB signaling and survival of lymphoma cells by regulating TRAF2 expression.
  8. (2009). EBV Zta protein induces the expression of interleukin-13, promoting the proliferation of EBVinfected B cells and lymphoblastoid cell lines.
  9. (2005). Epstein-Barr virus (EBV) latent membrane protein 2A regulates B-cell receptor-induced apoptosis and EBV reactivation through tyrosine phosphorylation.
  10. (2004). Epstein-Barr virus (EBV) LMP2A alters normal transcriptional regulation following B-cell receptor activation.
  11. (2004). Epstein-Barr virus (EBV) LMP2A mediates B-lymphocyte survival through constitutive activation of the Ras/PI3K/Akt pathway.
  12. (1994). Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state.
  13. (1992). Epstein-Barr virus latent gene expression in uncultured peripheral blood lymphocytes.
  14. (2007). Epstein-Barr virus latent membrane protein 2A is a B-cell receptor mimic and essential for Bcell survival.
  15. Epstein-Barr virus LMP2A accelerates MYC-induced lymphomagenesis.
  16. (2005). Epstein-Barr virus LMP2A alters in vivo and in vitro models of B-cell anergy, but not deletion, in response to autoantigen.
  17. (1998). Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals.
  18. (2006). Epstein-Barr virus LMP2A enhances B-cell responses in vivo and in vitro.
  19. (2000). Epstein-Barr virus LMP2A-induced B-cell survival in two unique classes of EmuLMP2A transgenic mice.
  20. (1994). Epstein-Barr virus protein LMP2A regulates reactivation from latency by negatively regulating tyrosine kinases involved in sIg-mediated signal transduction. Infect Agents Dis 3,
  21. (2004). Epstein-Barr virus-encoded LMP2A regulates viral and cellular gene expression by modulation of the NF-kB transcription factor pathway.
  22. (2001). Epstein-Barr virus: exploiting the immune system.
  23. (2006). IL-10 can induce the expression of EBV-encoded latent membrane protein-1 (LMP-1) in the absence of EBNA-2 in B lymphocytes and in Burkitt lymphoma- and NK lymphoma-derived cell lines.
  24. (2010). IL-21 imposes a type II EBV gene expression on type III and type I B cells by the repression of Cand activation of LMP-1-promoter.
  25. (2008). Interleukin-21 regulates expression of key Epstein-Barr virus oncoproteins, EBNA2 and LMP1, in infected human B cells.
  26. (2009). Interleukin-21 regulates expression of the immediate-early lytic cycle genes and proteins in Epstein-Barr virus infected B cells.
  27. (1996). LMP2A protects B-cells from apoptosis via NF-kB and Bcl 2201Decker,
  28. (2009). Modulation of LMP2A expression by a newly identified Epstein-Barr virus-encoded microRNA miR-BART22.
  29. (1997). NF-kB RelA-deficient lymphocytes: normal development of T cells and B cells, impaired production of IgA and IgG1 and reduced proliferative responses.
  30. (1996). Regulation of Epstein-Barr virus latency by latent membrane protein 2.
  31. (2000). Rel/NF-kB transcription factors: key mediators of B-cell activation.
  32. (2004). T-cell-receptor- and B-cell-receptormediated activation of NF-kB in lymphocytes.
  33. (2000). The anti-apoptotic activities of Rel and RelA required during B-cell maturation involve the regulation of Bcl2 expression.
  34. (2008). The curious case of the tumour virus: 50 years of Burkitt’s lymphoma.
  35. (2001). The Epstein-Barr virus encoded latent membrane protein 2A augments signaling from latent membrane protein 1.
  36. (2000). The expression pattern of Epstein-Barr virus latent genes in vivo is dependent upon the differentiation stage of the infected B cell.
  37. (2000). Tonsillar memory B cells, latently infected with Epstein-Barr virus, express the restricted pattern of latent genes previously found only in Epstein-Barr virusassociated tumors.